

## OVERVIEW – Thursday, 29 September 2011

Room	Plenary	Harvard	Stanford	Princeton	Yale 2	Foyer	
Time							
09.30 – 10.15	<b>Opening Ceremony</b>					<b>Registration Counter</b> Opening Hours: 08.00 – 18.00	
10.15 – 11.00	<b>PL-01</b> A hundred years of schizophrenia: from Bleuler to DSM-V/ ICD-11						
<b>Coffee Break</b>							
11.30 – 13.00	<b>S-01</b> Developments in DSM-V and ICD-11 with respect to schizophrenia	<b>S-02</b> Suicide and suicidal behavior in recent onset psychotic disorders	<b>S-03</b> Brain imaging in the early stages of schizophrenia	<b>S-04</b> Advances in animal models of schizophrenia: genes, environment, and prevention to biological foundations			
13.00 – 14.30	<b>Lunch Break</b> <b>13.30 – 14.30 h ▶ Guided Poster Sessions P-01 to P-03</b> P-01: Drug treatment I: Clinical   P-02: Co-morbidity   P-03: Neuroimaging						
14.30 – 16.00	<b>S-05</b> The future of psychiatric genetics beyond GWAS	<b>S-06</b> Efficacy and mechanisms of cognitive behavior therapy for psychosis results of the POSITIVE network	<b>S-07</b> Insight in psychosis: cognitive and neural basis, and implications for treatment	<b>S-08</b> Neuroprotective strategies in schizophrenia	<b>W-01</b> MedicaWiki: a webbased independent evidence based psychopharmacological prescription decision system		
<b>Coffee Break</b>							
16.30 – 18.00	<b>S-09</b> Novel therapeutic targets for treating schizophrenia	<b>S-10</b> Cognitive behaviour therapy for psychosis: what do we know about its effectiveness and neural correlates?	<b>O-01</b> Co-morbidity	<b>S-11</b> Motor symptoms as an intrinsic component of schizophrenia pathobiology			
18.00 – 19.00	<b>Welcome Reception in the Foyer</b>						

### Abbreviations

<b>PL</b> – Plenary Lecture	<b>W</b> – Workshop
<b>S</b> – Symposium	<b>O</b> – Oral Presentation

## OVERVIEW – Friday, 30 September 2011

Room Time	Plenary	Harvard	Stanford	Princeton	Yale 2	Foyer	
08.30 – 10.00	<b>S-12</b> Negative symptoms of schizophrenia: assessment, domains and relationships with outcome	<b>S-13</b> Antipsychotics in the elderly	<b>S-14</b> Glutamate dysfunction in schizophrenia and bipolar disorder: evidence from genetics and brain imaging	<b>O-02</b> Epidemiology and clinical phenotypes		<b>Registration Counter</b> Opening Hours: 08.00 – 18.30	
<b>Coffee Break</b>							
10.30 – 12.00	<b>S-15</b> Cognition in schizophrenia: from neural mechanisms to psychological interventions	<b>S-16</b> EPA position statements concerning schizophrenia and beyond	<b>S-17</b> Social cognition and violent behavior in schizophrenia	<b>O-03</b> Early stages of schizophrenia			
12.15 – 13.00	<b>PL-02</b> Schizophrenia treatment and prevention – facts and visions						
13.00 – 14.30	<b>Lunch Break</b> <b>13.30 – 14.30 h ▶ Guided Poster Sessions P-04 to P-07</b> P-04: Epidemiology, diagnosis   P-05: Genetics, neurotransmission P-06: Neurobiology   P-07: Drug treatment II: Basic						
14.30 – 16.00	<b>W-02</b> Past, current and future European schizophrenia research projects	<b>O-04</b> Drug and other somatic treatments	<b>S-18</b> Schizophrenia – a mild encephalitis?	<b>S-19</b> Psychomotor symptoms in schizophrenia	<b>W-03</b> Writing manuscripts for publication in English language scientific journals		
<b>Coffee Break</b>							
16.30 – 18.00	<b>S-20</b> Toxicity of relapse	<b>S-21</b> Co-morbidity of schizophrenia and physical illness	<b>S-22</b> Advances in understanding the causes of schizophrenia	<b>S-23</b> PREVENT: a multidimensional study of people at risk to develop first episode psychosis:...	until 17.30 h		
18.15 – 19.45		<b>S-24</b> Strength based treatment in an early psychosis ACT team: engaging the troublesome avoiders	<b>S-25</b> Psychotic symptoms in schizophrenia – biological correlates, clinical outcome and therapeutic consequences	<b>O-05</b> Psychosocial treatment			

## OVERVIEW – Saturday, 1 October 2011

Room Time	Plenary	Harvard	Stanford	Princeton	Foyer	
08.30 – 10.00	<b>S-26</b> Psychosis: psychological therapies and their mechanisms of action	<b>S-27</b> First-episode programmes: concepts and proven evidence	<b>S-28</b> Dopaminergic and glutamatergic dysfunction in schizophrenia	<b>O-06</b> Genetics and neurobiology	<b>Registration Counter</b> Opening Hours: 08.00 – 16.00	
<b>Coffee Break</b>						
10.30 – 12.00	<b>W-04</b> European practice guidelines: a need for harmonisation?	<b>S-29</b> Understanding minds: a conceptual framework in the research and clinical features of schizophrenia	<b>S-30</b> Early recognition and early intervention: facts and visions	<b>S-31</b> Animal models of schizophrenia between genotype, endophenotype, nongenetic second hit and the disease		
12.15 – 13.00	<b>PL-03</b> Social cognition and schizophrenia					
13.00 – 14.30	<b>Lunch Break</b> <b>13.30 – 14.30 h ► Guided Poster Sessions P-08 to P-11</b> P-08: Outcome   P-09: Neuropsychology I: Basic P-10: Neuropsychology II: Clinical   P-11: Psychosocial treatment					
14.30 – 16.00	<b>S-32</b> Classification of different long-term outcomes of psychosis in schizophrenia spectrum – a need for re-conceptualization	<b>S-33</b> Molecular linkage between energy metabolism and oligodendrocyte pathology in schizophrenia	<b>S-34</b> Heterogeneity and functional significance of white matter changes in schizophrenia	<b>O-07</b> Neuropsychology and neuroimaging		